Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Slipping Today

By Keith Speights - Updated Mar 17, 2021 at 11:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be skittish about the Fed's meeting today.

What happened

Shares of Moderna (MRNA 8.79%) were 5.4% lower as of 10:36 a.m. EDT on Wednesday even though the biotech didn't announce any news that would cause its shares to fall.

So what's the culprit behind today's decline? Biotech stocks are sliding in general. The two major biotech exchange-traded funds (ETFs) -- iShares Nasdaq Biotechnology ETF and SPDR S&P Biotech ETF -- are both down, as investors appear to be nervous because of the Federal Reserve Board meeting today.

So what

There's a simple reason biotech stocks (and other stocks as well) are volatile ahead of the Fed's conclusion of its two-day meeting: It's possible that the central bank could raise interest rates. If that happens, stocks would be less attractive to investors in comparison to other assets such as bonds because yields increase as interest rates increase.

Scientist holding a syringe and a vaccine vial

Image source: Getty Images.

Moderna likely fell harder than some other biotech stocks because investors think it's valued at a premium price. The important thing to recognize, however, is that Moderna's fortunes depend much more on the demand for COVID-19 vaccines after 2021 and the company's pipeline progress than they do on interest rate fluctuations.

Now what

Moderna has a couple of clinical studies underway that investors will want to watch closely. It's evaluating COVID-19 vaccine mRNA-1273 in a phase 2/3 study in children between ages six months and under 12 years. The biotech is also evaluating a next-generation COVID-19 vaccine, mRNA-1283, in an early-stage clinical study. This vaccine candidate could be stored at standard refrigerator temperatures and could potentially be a single-dose regimen.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$147.74 (8.79%) $11.94
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
$119.15 (2.89%) $3.35
SPDR Series Trust - SPDR S&P Biotech ETF Stock Quote
SPDR Series Trust - SPDR S&P Biotech ETF
$71.00 (3.69%) $2.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.